Prof Ghosh presented data from the UNITI studies exploring ustekinumab in primary or secondary nonresponders to TNF agonists (UNITI-1) and conventional therapy failures (UNITI-2).
Risk Factors and Prevention of Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis: An Update
19 Mins
